In the quest to be healthy, dietary supplements continue to be a popular option with some people but the U.S. Food and Drug Administration’s recent warnings to companies hawking such products should cause potential customers to proceed with caution. The agency recently sent out warnings to several companies that it said did not adhere to government guidelines on dietary supplement claims and their purported benefits. … Continue reading FDA Warning: Dietary supplements from these 12 companies may not be what they seem
The Food and Drug Administration on Friday approved what is being called the most expensive drug in the world. Novartis’ Zolgensma is a one-time injection used to treat children with spinal muscular atrophy at a cost of $2.13 million, reports CNBC. If left untreated, the condition leads to loss of muscle function. Severe cases can result in death. Current treatments for the disease require regular … Continue reading FDA: The world’s most-expensive drug, APPROVED.
Kaiser Health News | By Jon Greenberg, PolitiFact May 8, 2019 If there’s one area of health care where Republicans and Democrats might strike a deal, it’s prescription drugs. President Donald Trump has floated a plan to cut drug prices. Democratic and Republican ideas abound in Congress, where lawmakers have put more than 40 bills on the table. In 2018, 39 states passed 94 laws targeting pricing … Continue reading The Money And Politics Of Prescription Drugs: What You Need To Know
Dr. Clint Flanagan, Founder and CEO of Nextera Healthcare is a recognized leader in healthcare. Furthermore, the Nextera Healthcare team of Physicians and its growing network is today, well-known for taking its unique brand of Direct Primary Care to a massive amount of people. Through Nextera Healthcare’s innovative partnerships and relationships with Doctors, Employers and Businesses, C-Suite Owners and Operators are starting to straighten up … Continue reading NEW | DocPreneur Podcast | Listen | EP 241 | Nextera Healthcare Founder & CEO Dr Clint Flanagan on DPC to Employers, Part 1